Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $25.9 million.

  • Protagonist Therapeutics' Cash from Financing Activities fell 53.04% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 7.65%. This contributed to the annual value of $25.9 million for FY2024, which is 84.83% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Cash from Financing Activities stood at $25.9 million for FY2024, which was down 84.83% from $170.5 million recorded in FY2023.
  • Protagonist Therapeutics' 5-year Cash from Financing Activities high stood at $247.6 million for FY2020, and its period low was $18.8 million during FY2022.
  • Its 3-year average for Cash from Financing Activities is $71.7 million, with a median of $25.9 million in 2024.
  • As far as peak fluctuations go, Protagonist Therapeutics' Cash from Financing Activities plummeted by 85.50% in 2022, and later spiked by 804.96% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Cash from Financing Activities (Yearly) stood at $247.6 million in 2020, then tumbled by 47.53% to $129.9 million in 2021, then tumbled by 85.50% to $18.8 million in 2022, then surged by 804.96% to $170.5 million in 2023, then crashed by 84.83% to $25.9 million in 2024.